Stroke
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) aged 18-80 years old (2) Patients with acute ischemic stroke or TIA diagnosed by cranial MRI or CT examination in accordance with the criteria of the 2018 China Acute Ischemic Stroke Diagnosis and Treatment Guidelines; and (3) Received intravenous thrombolytic therapy: alteplase dosage was 0.9 mg/kg, with a maximum of 90 mg per patient. 10% of the therapeutic alteplase was injected slowly intravenously over 1 minute, and the remaining 90% was administered homogenously over 60 minutes via an intravenous minipump. (4) Agreed to participate in this study and gave informed consent for case data collection and preservation and follow-up process.
Exclusion criteria
Exclusion criteria: (1) Intracranial hemorrhagic disease as seen on cranial CT; (2) Dementia or psychiatric problems that preclude cooperation with follow-up; (3) Presence of claustrophobia, presence of implanted metallic substances that preclude cranial MR examination; (4) Presence of severe hepatic and renal impairment (5) Failure to sign an informed consent form; (6) Any other condition that the investigator considers unsuitable for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| New ischemic or hemorrhagic stroke at 180 days; | — |
Secondary
| Measure | Time frame |
|---|---|
| New stroke within 30 days;Vascular events at 90 days;Severe or moderate bleeding within 180 days;Any hemorrhage, death, adverse events and serious adverse events at 180 days follow-up; | — |
Countries
Chnia
Contacts
Dalian Municipal Central Hospital